Table 1.
Hypoglycaemia risk comparison of participants with T2DM treated with Gla-300 versus Gla-100
| Risk index | EDITION 2 | EDITION 3 | SENIOR | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gla-300 | Gla-100 | p value | Gla-300 | Gla-100 | p value | Gla-300 | Gla-100 | p value | |
| LBGI | |||||||||
| Titration | 0.33 | 0.51 | < 0.0001 | 0.24 | 0.30 | 0.0587 | 0.28 | 0.34 | 0.1167 |
| Maintenance | 0.41 | 0.50 | 0.043 | 0.38 | 0.41 | 0.4205 | 0.34 | 0.44 | 0.0125 |
| Overall p value | 0.0003 | 0.1012 | 0.0084 | ||||||
| Nocturnal LBGI | |||||||||
| Titration | 0.72 | 1.29 | < 0.0001 | 0.50 | 0.59 | 0.1838 | 0.39 | 0.51 | 0.0604 |
| Maintenance | 0.98 | 1.24 | 0.0387 | 0.73 | 0.92 | 0.0176 | 0.52 | 0.67 | 0.0270 |
| Overall p value | < 0.0001 | 0.0167 | 0.0082 | ||||||
The data points represent mean values unless otherwise indicated
Gla-100 insulin glargine 100 U/mL, Gla-300 insulin glargine 300 U/mL, LBGI low blood glucose index
p value represents treatment differences between Gla-300 and Gla-100 within the titration, maintenance or overall (titration and maintenance) trial periods